Intracranial ependymomas represent a rare subgroup of glial tumours, showing a wide variety of imaging characteristics, often representing a challenging diagnosis for neuroradiologists. Here, we review the most recent scientific Literature on intracranial ependymomas, highlighting the most characteristic computed tomography and magnetic resonance imaging features of these neoplasms, along with epidemiologic data, recent classification aspects, clinical presentation and conventional therapeutic strategies. In addition, we report an illustrative case of an 18-year-old girl presenting with an intracranial supratentorial, anaplastic ependymoma, with the aim of contributing to the existing knowledge and comprehension of this rare tumour.
VillanoJLParkerCKDolecekTA.Descriptive epidemiology of ependymal tumours in the United States. Br J Cancer2013;
108: 2367–2371.
2.
CrocettiETramaAStillerC, et al.
Epidemiology of glial and non-glial brain tumours in Europe. Eur J Cancer2012;
48: 1532–1542.
3.
AcheyRLVoSCioffiG, et al.
Ependymoma, NOS and anaplastic ependymoma incidence and survival in the United States varies widely by patient and clinical characteristics, 2000–2016. Neurooncol Pract2020;
7: 549–558.
4.
CampianJGutmannDH.CNS tumors in neurofibromatosis. J Clin Oncol2017;
35: 2378–2385.
5.
BiZRenXZhangJ, et al.
Clinical, radiological, and pathological features in 43 cases of intracranial subependymoma. J Neurosurg2015;
122: 49–60.
6.
ThompsonYYRamaswamyVDiamandisP, et al.
Posterior fossa ependymoma: current insights. Childs Nerv Syst2015;
31: 1699–1706.
7.
LouisDNOhgakiHWiestlerOD, et al.
The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol2007;
114: 97–109.
8.
PajtlerKWMackSCRamaswamyV, et al.
The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathol2017;
133: 5–12.
LesterAMcDonaldKL.Intracranial ependymomas: molecular insights and translation to treatment. Brain Pathol2020;
30: 3–12.
11.
FukuokaKKanemuraYShofudaT, et al.
Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors. Acta Neuropathol Commun2018;
6: 134.
12.
MacKSCWittHPiroRM, et al.
Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature2014;
506: 445–450.
13.
ShimadaSIshizawaKHoriguchiH, et al.
Subependymoma of the spinal cord and review of the literature. Pathol Int2003;
53: 169–173.
14.
RagelBTOsbornAGWhangK, et al.
Subependymomas: an analysis of clinical and imaging features. Neurosurgery2006;
58: 881–890.
15.
ImSHPaekSHChoiY La, et al.
Clinicopathological study of seven cases of symptomatic supratentorial subependymoma. J Neurooncol2003;
61: 57–67.
16.
NeumannJESpohnMObrechtD, et al.
Molecular characterization of histopathological ependymoma variants. Acta Neuropathol2020;
139: 305–318.
17.
KumariaAChanHWGoldspringRJ, et al. Isolated myxopapillary ependymoma of the fourth ventricle: case report and review of literature. Br J Neurosurg. Epub ahead of print 13 October 2018. DOI: 10.1080/02688697.2018.1524847.
18.
AbdallahAEmelEGündüzHB, et al.
Long-term surgical resection outcomes of pediatric myxopapillary ependymoma: experience of two centers and brief literature review. World Neurosurg2020;
136: e245–e261.
19.
MewadaTBBishnoiIHSinghH, et al.
Occipital Intraparenchymal myxopapillary ependymoma: case report and literature review. Asian J Neurosurg2017;
12: 731–734.
20.
YuhELBarkovichAJGuptaN.Imaging of ependyomomas: MRI and CT. Childs Nerv Syst2009;
25: 1203–1213.
21.
SantoshVMangaloreSAryanS, et al.
Imaging characteristics of supratentorial ependymomas: study on a large single institutional cohort with histopathological correlation. Asian J Neurosurg2015;
10: 276–281.
22.
PfisterSHartmannCKorshunovA.Histology and molecular pathology of pediatric brain tumors. J Child Neurol2009;
24: 1375–1386.
23.
LengXTanXZhangC, et al.
Magnetic resonance imaging findings of extraventricular anaplastic ependymoma: a report of 11 cases. Oncol Lett2016;
12: 2048–2054.
24.
VarrassiMCobianchi BellisariFBrunoF, et al.
High-resolution magnetic resonance imaging at 3T of pituitary gland: advantages and pitfalls. Gland Surg2019;
8: S208–S215.
25.
OnishiSYamasakiFNakanoY, et al.
RELA fusion-positive anaplastic ependymoma: molecular characterization and advanced MR imaging. Brain Tumor Pathol2018;
35: 41–45.
JinBFengXY.MRI features of atypical teratoid/rhabdoid tumors in children. Pediatr Radiol2013;
43: 1001–1008.
28.
TaschnerCAStaszewskiOZentnerJ, et al.
Freiburg neuropathology case conference: a mass lesion of the mesial temporal lobe in a child. Clin Neuroradiol2011;
21: 171–176.
VarrassiMCorridoreATommasinoE, et al. Correction to: MR imaging of cerebral involvement of Rosai-Dorfman disease: a single-centre experience with review of the literature. Radiol Med. 2020 Aug 18. doi: 10. 1007/s11547-020-01257-0. Epub ahead of print. Erratum for: Radiol Med. 2020: PMID: 32809174.
31.
WaniKArmstrongTSVera-BolanosE, et al.
A prognostic gene expression signature in infratentorial ependymoma. Acta Neuropathol2012;
123: 727–738.
32.
RaghunathanAWaniKArmstrongTS, et al.
Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system. Brain Pathol2013;
23: 584–594.
33.
OstromQTGittlemanHTruittG, et al.
CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015.Neuro Oncol2018;
20: iv1–iv86.
34.
PajtlerKWWittHSillM, et al.
Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell2015;
27: 728–743.
35.
RogersLPueschelJSpetzlerR, et al.
Is gross-total resection sufficient treatment for posterior fossa ependymomas?J Neurosurg2005;
102: 629–636.
36.
RudàRReifenbergerGFrappazD, et al.
EANO guidelines for the diagnosis and treatment of ependymal tumors. Neuro Oncol2018;
20: 445–456.
37.
MerchantTEFouladiM.Ependymoma: new therapeutic approaches including radiation and chemotherapy. J Neurooncol2005;
75: 287–299.
38.
GhiaAJMahajanAAllenPK, et al.
Supratentorial gross-totally resected non-anaplastic ependymoma: population based patterns of care and outcomes analysis. J Neurooncol2013;
115: 513–520.
39.
AmirianESArmstrongTSAldapeKD, et al.
Predictors of survival among pediatric and adult ependymoma cases: a study using surveillance, epidemiology, and end results data from 1973 to 2007. Neuroepidemiology2012;
39: 116–124.
40.
HollonTNguyenVSmithBW, et al.
Supratentorial hemispheric ependymomas: an analysis of 109 adults for survival and prognostic factors. J Neurosurg2016;
125: 410–418.
41.
MerchantTELiCXiongX, et al.
Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. Lancet Oncol2009;
10: 258–266.
42.
MerchantTEMulhernRKKrasinMJ, et al.
Preliminary results from a Phase II trial of conformal radiation therapy and evaluation of radiation-related CNS effects for pediatric patients with localized ependymoma. J Clin Oncol2004;
22: 3156–3162.
43.
GeyerJRSpostoRJenningsM, et al.
Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children’s Cancer Group. J Clin Oncol2005;
23: 7621–7631.
44.
KoshyMRichSMerchantTE, et al.
Post-operative radiation improves survival in children younger than 3 years with intracranial ependymoma. J Neurooncol2011;
105: 583–590.
45.
KalfasFScudieriC.World Health Organization grade III supratentorial extraventricular ependymomas in adults: case series and review of treatment modalities. Asian J Neursurg2019;
14: 1157–1164.
46.
MassiminoMMiceliRGiangasperoF, et al.
Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma. Neuro Oncol2016;
18: 1451–1460.
47.
WuJArmstrongTSGilbertMR.Biology and management of ependymomas. Neuro Oncol2016;
18: 902–913.
48.
MacDonaldSMLaackNNTerezakisS.Humbling advances in technology: protons, brainstem necrosis, and the self-driving car. Int J Radiat Oncol Biol Phys2017;
97: 216–219.
49.
KhatuaSRamaswamyVBouffetE.Current therapy and the evolving molecular landscape of paediatric ependymoma. Eur J Cancer2017;
70: 34–41.
50.
GrundyRGWilneSAWestonCL, et al.
Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study. Lancet Oncol2007;
8: 696–705.
51.
GarvinJHSelchMTHolmesE, et al.
Phase II study of pre-irradiation chemotherapy for childhood intracranial ependymoma. Children’s Cancer Group protocol 9942: A report from the Children’s Oncology Group.Pediatr Blood Cancer2012;
59: 1183–1189.
52.
RehmanSBrockCNewlandsES.A case report of a recurrent intracranial ependymoma treated with temozolomide in remission 10 years after completing chemotherapy. Am J Clin Oncol Cancer Clin Trials2006;
29: 106–107.
53.
KhooHMKishimaHKinoshitaM, et al.
Radiation-induced anaplastic ependymoma with a remarkable clinical response to temozolomide: a case report. Br J Neurosurg2013;
27: 259–261.
54.
LombardiGPambukuABelluL, et al.
Cisplatin and temozolomide combination in the treatment of supratentorial anaplastic ependymoma. Chemotherapy2013;
59: 176–180.
55.
RudàRBosaCMagistrelloM, et al.
Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study. Neuro Oncol2016;
18: 261–268.
56.
GilbertMYuanYWaniK, et al.
AT-23 A Phase II study of lapatinib and dose-dense temozolomide (TMZ) for adults with recurrent ependymoma: a CERN clinical trial. Neuro Oncol2014;
16: v13.
57.
GreenRMCloughesyTFStuppR, et al.
Bevacizumab for recurrent ependymoma. Neurology2009;
73: 1677–1680.
58.
WittHMackSCRyzhovaM, et al.
Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell2011;
20: 143–157.
59.
ParkerMMohankumarKMPunchihewaC, et al.
C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma. Nature2014;
506: 451–455.
60.
GodfraindCKaczmarskaJMKocakM, et al.
Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas. Acta Neuropathol2012;
124: 247–257.
61.
GaudinoSMarzialiGPezzulloG, et al.
Role of susceptibility-weighted imaging and intratumoral susceptibility signals in grading and differentiating pediatric brain tumors at 1.5 T: a preliminary study. Neuroradiology2020;
62: 705–713.
62.
MohammedWXunningHHaibinS, et al.
Clinical applications of susceptibility-weighted imaging in detecting and grading intracranial gliomas: a review. Cancer Imaging2013;
13: 186–195.
